Clinical trial
Impact of Dyslipidemia on Metabolic Health of Adults With Overweight/Obesity (IDOM): An Observational, Retrospective Cohort Study at the San Raffaele Hospital Center for Metabolic Health
NCT07919158 is registered in ClinicalTrials.gov with Rovere Querini Patrizia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Impact of Dyslipidemia on Metabolic Health of Adults With Overweight/Obesity (IDOM): An Observational, Retrospective Cohort Study at the San Raffaele Hospital Center for Metabolic Health
- Lead sponsor
- Rovere Querini Patrizia
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- October 1, 2024
- Completion date
- May 31, 2027
- Enrollment
- 900 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
dyslipidemia, obesity & overweight
Arms
As registered; 1 arm.
-
PATIENTS WITH OVERWEIGHT OR OBESITY
* Age ≥ 18 years; overweight/obesity.
* BMI ≥ 25 kg/m2
* Availability of complete baseline Iipid profile (TC, LDL.-C, TG, HDL-C) No additional intrventions.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
To estimate the prevalence of dyslipidemia and assess its association with metabolic health in adults with overweight or obesity.
1a. Prevalence of dyslipidemia (≥1 lipid criterion met): TC ≥200 mg/dL; fasting TG ≥150 mg/dL; HDL \<40 mg/dL (men) or \<50 mg/dL (women); LDL exceeding risk-category-specific threshold (\>116 / \>100 / \>70 / \>55 mg/dL for low / moderate / high / very high CV risk).
1b. Odds ratio (OR) for dyslipidemia across metabolic categories (intermediate vs. healthy; unhealthy vs. healthy).
Metabolic health score (0-5): 1 point each for: (1) fasting glucose ≥100 mg/dL or HbA1c ≥5.7% or antidiabetic therapy; (2) SBP ≥130 or DBP ≥85 mmHg or antihypertensive therapy; (3) waist circumference ≥94 cm (men) / ≥80 cm (women); (4) hs-CRP \>0.3 mg/dL, (5) history of liver steatosis.
Lipid parameters excluded to avoid circularity. Categories: healthy (0), intermediate (1-2), unhealthy (≥3).
Lead sponsor's other trials
Rovere Querini Patrizia, most recent start first.
Similar trials
Same condition (Dyslipidemias) and phase, most recent start first.
+217 more trials See the condition page